2024 Retinal Pharmaceuticals Market Report: Wet AMD and Other Exudative Diseases, September, 2024

The “2024 Retinal Pharmaceuticals Market Report: Wet AMD and Other Exudative Diseases” analyzes the market for anti-VEGFs and other drugs for the treatment of exudative retinal diseases. The report discusses important trends, analyzes key factors for future market success, examines the market’s evolution, and forecasts growth over the next five years. Product demand is forecast in units and dollars, and market shares are analyzed by product category. Additionally, 40 competitors are profiled, with discussion of their products, strategic market position, background, and outlook. 

The report explores a variety of topics intended to provide depth and context to the understanding of market dynamics in this ophthalmic segment. Our coverage includes: 

• Discussions of retinal diseases and their risk factors. 
• Diagnosis and treatment of these diseases. 
• A global view of retinal care and retina specialists. 
• A review of pharmaceuticals and biologics for exudative retinal diseases in the marketplace. 
• Analysis of investigational agents in the development pipeline. 
• Profiles of companies developing and marketing pharmaceuticals for exudative retinal diseases, plus a listing of additional companies with preclinical programs. 

The report provides market forecasts for branded ocular anti-VEGFs, cancer drugs used off label, and biosimilars used for the treatment of exudative retinal diseases. The report also includes a separate forecast for sustained-drug-delivery devices in the treatment of such diseases. 

The report delves into the development pipelines of eight categories of retinal pharmaceuticals: 

• VEGF inhibitors 
• Other vascular growth factor inhibitors 
• Plasma kallikrein inhibitors 
• Gene therapies 
• Cell therapies 
• Anti-inflammatories 
• Wnt signaling  
• Other mechanisms of action 

2 licensing types are available for this report:

• The price of the single-user license is $8,650.
• The price of the enterprise license is $12,975 (includes supplemental Excel file with all the tables and figures in the report, and report summary slides).

Both licenses include an electronic PDF. Printed copies may be purchased for an additional $250.

SINGLE USER LICENSE

• The Single User License allows for the use of a report by a single user within one corporate location.
• The report paper copy may not be reproduced (additional paper copies available for purchase).
• Report PDF copy can not be copied (if purchased) and must remain on one computer (not a company server).
• Only a single copy of the publication may be printed for internal use.
• Users may include information in the report in presentations and internal reports by providing full copyright credit to Market Scope.
• Users may not share the report (or any information contained therein) with any other person or persons outside the corporate location for which the report is purchased.

ENTERPRISE LICENSE

• The Enterprise License allows for the use of a report by unlimited users within the purchasing organization.
• Purchasing organization shall have the right to share the report with third parties. (investors, consultants, etc.) from time to time under the global license agreement, provided that such third parties have a confidentiality agreement with the purchasing organization and agree to be bound by the terms of the global license agreement.
• Employees of the purchasing organization can include information given in the report in presentations and internal reports by providing full copyright credit to Market Scope.
• Purchase price includes a printable PDF file of the report (purchasing organization may print multiple copies for use within the organization).
• Purchase price includes a supplemental Excel file containing all the tables and figures included in the purchased report.

Pay by credit card or by invoice.